Lantheus Stock May Be 14% Undervalued After BRAVNETSA FDA Approval
Lantheus’ BRAVNETSA approval may support a 14% fair-value gap, but SPARROW timing and capital needs remain key variables.
AbbVie’s Parkinson’s Drug Approval Fails to Lift Shares as ABBV Slips Nearly 1%
AbbVie won FDA approval for Juvmo, yet ABBV slipped nearly 0.8% as investors weighed expectations, market weakness and execution risks.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Egetis Shares Jump 13.2% After FDA Approves First MCT8 Deficiency Treatment
Egetis shares rose 13.2% after FDA approval of EMCITATE, putting rare-disease strategy and U.S. commercial questions in …
FDA Expands Eli Lilly’s Olumiant Label to Adolescents With Severe Alopecia
The FDA approved Eli Lilly’s once-daily Olumiant for adolescents with severe alopecia areata, expanding the commercial r…
AbbVie’s Reported $10.9 Billion Apogee Deal Puts Pharma M&A and Pipeline Risk in Focus
AbbVie’s reported $10.9 billion Apogee deal highlights pipeline strategy, capital allocation and potential volatility fo…
MediciNova Stock Falls 14.7% After Mixed Phase 2 NAFLD Results
MediciNova shares fell 14.7% in premarket trading after mixed Phase 2 results for tipelukast highlighted the binary risk…
AbbVie Wins FDA Approval for Juvmo, but Medicare Timing Could Slow the Parkinson’s Drug Launch
AbbVie’s Juvmo won FDA approval, but missing Medicare’s 2027 window could make the drug’s U.S. launch slower than the re…
Kodiak Sciences Stock Jumps 90% on Positive Phase 3 AMD Data: What Traders Should Watch Next
Kodiak Sciences shares surged as much as 90% premarket after positive Phase 3 AMD data. Here is what traders may watch n…
Zymeworks Updates 2026 Guidance After Finalizing Theravance Biopharma Deal
Zymeworks has updated its 2026 guidance after finalizing its Theravance Biopharma acquisition, giving investors a cleare…
Kodiak Sciences’ KOD Stock Jumps 65% After DAYBREAK Phase 3 Success
Kodiak Sciences shares reached $54.42 in premarket trading after DAYBREAK met primary endpoints for two eye-treatment ca…
AbbVie’s Parkinson’s Drug Approval Gives ABBV Stock a New October Catalyst
FDA approval for Juvmo gives AbbVie a potential post-Humira growth catalyst ahead of its planned October 2026 U.S. launc…